Question 1

Which loses more weight, Wegovy or Foundayo?

Accepted Answer

Wegovy edges Foundayo by roughly 3-4 percentage points across non-head-to-head pivotal trials. STEP-1 (Wilding 2021 NEJM, PMID 33567185) showed Wegovy 2.4 mg produced −14.9% total body weight at 68 weeks. ATTAIN-1 (Wharton 2025 NEJM, PMID 40960239) showed Foundayo at the FDA-approved 17.2 mg maintenance dose produced −11.1% body weight at 72 weeks. No direct head-to-head RCT exists yet, so cross-trial comparison comes with caveats — but the magnitude favors Wegovy modestly. For most patients, the 3-point gap is smaller than the gap between either drug and lifestyle alone.

Question 2

Should I pick the pill if I'm needle-averse?

Accepted Answer

Yes — Foundayo is a strong pick for injection-averse patients. Unlike Rybelsus (oral semaglutide), which only delivers about 3-5% weight loss because peptides poorly survive oral absorption, Foundayo is a non-peptide small molecule designed for oral bioavailability from the start. You give up roughly 3-4 percentage points of efficacy versus Wegovy but avoid weekly injections entirely. For patients who cite injection fear as a barrier to starting GLP-1 therapy, Foundayo is a meaningfully better oral option than Rybelsus.

Question 3

Does Foundayo need fasting like Rybelsus does?

Accepted Answer

No. Foundayo's non-peptide pharmacology means food and water do not meaningfully affect absorption — you take it any time of day, with or without meals, per the FDA prescribing information (DailyMed SetID 8ac446c5-feba-474f-a103-23facb9b5c62). This is a major practical advantage over Rybelsus, which requires an empty stomach, no more than 4 oz of plain water, and a 30-minute fast afterward. Wegovy is a weekly injection with no food-timing requirement either. So on the food-restriction axis, Foundayo and Wegovy tie — both fit easily into normal eating patterns.

Question 4

Are both covered by insurance?

Accepted Answer

Wegovy coverage is widespread where employer plans include an obesity benefit — most commercial plans cover it after BMI ≥30 (or ≥27 with comorbidity) plus prior auth. Medicare does not cover Wegovy for weight loss but does cover it for cardiovascular risk reduction in patients with obesity and established CVD (per the SELECT indication). Foundayo coverage is still rolling out as of late 2025 / early 2026 — major PBMs are adding it to formularies but prior auth criteria vary. Verify with your specific plan before assuming either is covered.

Question 5

Which has cardiovascular outcome data?

Accepted Answer

Wegovy only. The SELECT trial (Lincoff 2023 NEJM, PMID 37952131) randomized 17,604 adults with obesity and established CV disease without diabetes; Wegovy 2.4 mg cut major adverse cardiovascular events (MACE) by 20% versus placebo over a mean 39.8 months. The FDA added cardiovascular risk reduction to the Wegovy label in March 2024. Foundayo's dedicated cardiovascular outcomes trial is still enrolling and has not read out — until it does, the drug has no MACE-reduction evidence. If proven CV protection drives your choice, Wegovy wins.

Question 6

How do the side effects compare?

Accepted Answer

Both are dominated by gastrointestinal effects — nausea, diarrhea, constipation, vomiting — typical of GLP-1 receptor activation regardless of route. In STEP-1, Wegovy 2.4 mg produced nausea in roughly 44% of patients; in ATTAIN-1, Foundayo 17.2 mg produced nausea in roughly 20-30% of patients (dose-dependent). Both carry the FDA boxed warning for thyroid C-cell tumors based on rodent data. Titration is gradual for both to minimize tolerability problems. Patients tend to find oral GLP-1 GI symptoms slightly easier to manage than injectable peaks, but the underlying receptor activation drives the same physiology.

Field	Wegovy	Foundayo
Route & frequency	Subcutaneous injection, once weekly	Oral tablet, once daily — any time, with or without food
Mechanism	Peptide GLP-1 receptor agonist (semaglutide)	Non-peptide small-molecule GLP-1 receptor agonist
Weight loss (pivotal trial, max dose)	−14.9% TBWL / 68 wk (STEP-1, 2.4 mg)	−11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg)
FDA-approved indication	Chronic weight management; CV risk reduction in obesity + CVD	Chronic weight management; type 2 diabetes
Dosing schedule	0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly (5-step titration)	0.8 → 1.6 → 3 → 5.5 → 9 → 14.5 → 17.2 mg daily (7-step titration)
Food / timing requirement	None (injectable)	None — with or without food, any time of day
Cardiovascular outcome	MACE −20% in obesity without diabetes (SELECT, 2023)	CV outcomes trial pending — no MACE data yet
Cash price (manufacturer direct, monthly)	$349-$499/mo via NovoCare	LillyDirect direct-pay tier rolling out 2026

Wegovy vs Foundayo (2026): Weekly Injection vs Daily Oral GLP-1

The verdict

Side-by-side comparison

Frequently asked questions